The pulmonary lymphatic vasculature plays a vital role in maintaining fluid homeostasis required for efficient gas exchange at capillary alveolar barriers and contributes to lung fluid clearance at birth. To further understanding of pulmonary lymphatic function at birth, lineage-tracing analysis of mouse lung was used. Lineage analysis confirmed that lymphatic endothelial cells (LEC) bud from extrapulmonary lymphatics and demonstrated that LEC migrate into developing lung along precise pathways. LEC cluster first in the primary bronchovascular region then along the secondary broncho-arterial regions and along veins.
Introduction
While development of the pulmonary blood vasculature through the processes of angiogenesis and vasculogenesis is well-studied (Galambos and deMello, 2007) , the ontogeny and mechanisms of lymphatic vascular development during lung organogenesis are less well understood. Lymphatics play a vital role in maintaining homeostasis by keeping tissues free of excess fluid. This function is especially important in lungs to facilitate efficient gas exchange at the capillary alveolar barrier. Further, at birth the pulmonary lymphatics contribute to lung fluid clearance. The inability to efficiently 0925-4773/$ -see front matter Ó 2010 Elsevier Ireland Ltd. All rights reserved. doi:10.1016/j.mod.2010.09.003 clear fetal lung fluid significantly contributes to respiratory distress of preterm infants (Helve et al., 2009) .
Central to understanding pulmonary lymphatic physiology in the neonate is determining when the lymphatic vasculature is fully patterned and functional. The morphology of the pulmonary lymphatic vasculature of adult and neonatal lung has been well characterized (Lauweryns and Boussauw, 1969; Leak and Jamuar, 1983; Peao et al., 1993 ). Yet, there is little knowledge on the developmental ontogeny of the lung lymphatics. Recent lineage-tracing analysis with Prox-1Cre-ERT2/R26R embryos by Srinivasan et al. (2007) , demonstrated that the lymphatic vasculature including that of the lung arises from sprouting, proliferation and migration of LEC originating from the jugular lymph sacs. These lymph sacs having formed from LEC sprouting off the cardinal vein (Wigle and Oliver, 1999) . At E16.5, the only lung stage reported, the lymphatic vasculature was detected from the central bronchovascular region to distal lung (Srinivasan et al., 2007) . We extended this study using whole mount and thin section analyses from E11.5 to birth to assess when lymphatics within primary and secondary bronchovascular regions and distal lymphatic vessels are established and remodeled to form a functional pulmonary vascular system. Activation of VEGF receptor 3 (VEGFR3) by ligands VEGF-C and VEGF-D generates essential signals for development and growth of the lymphatic vasculature (Makinen et al., 2007; Oliver, 2004) . Mutations of the tyrosine kinase domain of VEGFR3 are associated with lymphedema in humans and mice (Karkkainen et al., 2000) . Early in lung development the blood vascular network is composed of VEGFR2+/VEGFR3+ endothelial cells (EC). We found in lung that beginning at E14.5, lymphatic EC were VEGFR2+/VEGFR3+ while EC of the blood vasculature expressed only VEGFR2. Based on the exclusive expression of VEGFR3 on pulmonary lymphatics at later stages of lung organogenesis, we developed a lossof-function model with lung-specific and conditional expression of the extracellular ligand-binding domain of VEGFR3. We tested the hypothesis that dysregulation of VEGFR3 has detrimental effects on pulmonary lymphatic development and on lung function particularly during the birth process.
We report here that dnR3 expression during organogenesis leads to significant pulmonary lymphatic hypoplasia without altering lymphatic development in other organs or tissues or blood vascular development in the lung or lung organogenesis. Further, dnR3 expression in lung led to significant neonatal mortality caused by lymphatic hypoplasia that predisposes neonates to diminished lung fluid clearance and poor lung function at birth.
Results

Pulmonary lymphatic ontogeny
The discovery of lymphatic markers including Prox-1, LYVE-1 and VEGFR3 has made it possible to identify lymphatic vasculature with clear distinction from the blood vasculature (Oliver and Detmar, 2002) . For instance, lung lymphatic capillaries can be identified based on the expression of Prox-1 and their location within distal mesenchyme (Yuan et al., 2002) .
We extended the study of Srinivasan et al. (2007) using whole mount and thin section analyses to determine the developmental ontogeny of primary and secondary bronchovascular region lymphatics and distal lymphatic vessels in the developing lung from the embryonic stage, E11.5, through birth, E19.25. Pleural lymphatics were not included in these analyses. With dual immunofluorescence for Prox-1 and VEGFR3, markers of lymphatic EC, on thin sections of E11.5 lung, rare LEC were detected scattered in the distal lung mesenchyme (Fig. 1A, arrows) . Well-defined lymphatic vessels were detected in the extrapulmonary region adjacent to the budding lung (Fig. 1A) but not within the lung bud. For whole mount analysis, Prox-1-CreER T2 /R26R embryos were treated in utero with tamoxifin (TM) at E9.75 and lungs examined for LacZ+ LEC at E12.5 ( Fig. 1 ) and E13.5 (Fig. 2) . As mosaic labeling has been reported with this model (Srinivasan et al., 2007) , thin sections were also examined with immunohistochemistry for Prox-1 and LYVE-1. At E12.5 single LEC as well as clusters of LEC were found in the extrapulmonary regions along the foregut tube ( Fig. 1B and C, arrow) but only single cells were detected within the lung by both whole mount analysis ( Fig. 1B and C) and immunohistochemistry of a transverse thin sections for Prox-1 (Fig. 1D ) and LYVE-1 (Fig. 1E ). The Prox-1 and LYVE-1 positive LEC appear to follow a precise path into the lung mesenchyme. At E12.5 the blood vasculature is well established with primary blood vessels extending into each lobe (Fig. 1F , arrow) and a network of microvascular EC throughout the lung mesenchyme (Fig. 1F, arrowheads) . By E13.5, LacZ+ cells were detected in proximal and distal lung ( Fig. 2A) . Extensive staining in the region connecting the primary bronchus to each lobe (Fig. 2B ) indicated the primary lymphatics of the bronchopulmonary bundle were patterned between E12.5 and E13.5. Clusters of cells found along the primary pulmonary vein (Fig. 2C , arrow) and as single cells or small clusters of cells in distal lung (Fig. 2D, arrows) . Prox-1 immunohistochemistry at E14.5 detected lymphatic vessels with lumens in both proximal and distal bronchovascular bundles ( Fig. 2E and F) .
Just before birth, at E18.5, the lung lymphatic vasculature was well defined with many lymphatic vessels incorporated into proximal and the distal bronchovascular regions (Fig. 2G and H, arrowheads) . In proximal lung the bronchovascular region is composed of primary bronchioli with large arteries, veins and lymphatics associated within a loose extracellular matrix. In distal lung, veins are separated from broncho-arterial regions. Lymphatics are associated with both the secondary broncho-arterial regions and with veins. At E18.5, cells within the myofibroblast, smooth muscle cell layer of primary veins were Prox-1 positive (Fig. 2G ). Lymphatics were also detected within the intra-acinar mesenchyme ( Fig. 2H and J) . Historically, the lung lymphatic capillaries have been identified by ultrastructural analysis that included determining the vessel diameter, irregular wall structure, presence of lymph and anchoring filaments (Lauweryns and Boussauw, 1969; Leak and Jamuar, 1983) . Identification of these lymphatics as either small conducting lymphatics or lymphatic capillaries will require further analysis, including electron microscopy.
To assess whether new LEC contribute to lymphatic patterning throughout organogenesis, Prox-1-CreER T2 /R26R were treated with TM at E14.5 and lungs examined at E18.5 ( Fig. 2I and J). LacZ+ cells were detected throughout the lung with strong signal within the bronchovascular bundles ( Fig. 2I and J, arrows), also shown in thin section analysis (Fig. 2G,  arrowheads) . There was a regular pattern of LacZ+ cells in the distal lung mesenchyme (presumptive conducting lymphatics and capillaries) (Fig. 2J, arrowheads) . These data demonstrate that proliferating LEC contribute to all segments of the pulmonary lymphatic vasculature during lung organogenesis and confirm that expansion of the lymphatic vasculature continues throughout embryogenesis. Unclear is whether this new population of LEC derive from existing lymphatics within the lung, through continued migration from the extrapulmonary lymph sacs or through sprouting from pulmonary veins.
2.2.
Lung-specific dominant-negative expression of soluble VEGFR3
We used loss of function analysis to assess the role of pulmonary lymphatic development in overall lung organogenesis and to test the hypothesis that lymphatic function is critical during the transition period at birth. In distal lung from E11.5 through E13.5, the developing blood vascular network is composed of VEGFR3+/VEGFR2+ endothelial cells, E12.5 shown in Fig. 3A . From E14.5 on, VEGFR2/VEGFR3 dual positive cells were restricted to lymphatics while EC of the blood microvasculature were only VEGFR2 positive (Fig. 3B, E14 .5; C, E18.5). Based on the restricted expression of VEGFR3 on pulmonary lymphatics at later stages of lung organogenesis, we developed a dominant negative transgenic model with lung-specific and conditional expression of the extracellular ligand-binding domain of VEGFR3.
The dominant-negative VEGFR3 (dnR3) construct (Fig. 4A ) included the first three immunoglobulin (Ig)-like regions of murine VEGFR3 that incorporate the extracellular, ligandbinding domain joined with the Ig heavy chain hinge and Fc domains of mouse IgG to facilitate secretion (Celli et al., 1998) . To confer spatial expression, two well-characterized lung-specific activator lines were crossed independently or together with dnR3 animals to optimize dnR3 expression. The activator lines were SP-CrtTA (line 2) that express the reverse tetracycline transactivator (rtTA) only in type II pneumocytes (Tichelaar et al., 2000) and CCSPrtTA with rtTA expression in conducting airways and alveolar respiratory and LYVE-1 (E) positive LEC (arrows). (F) whole mount analysis of E12.5 lung from a FlklacZ embryo shows the primary blood vasculature (arrows) and microvascular network (arrowheads). In A, scale bar = 50 lm; in (D and E) scale bar = 100 lm. Br, bronchioli; lym, lymphatic; h, heart; f, foregut tube; l, lung.
epithelium (Tichelaar et al., 2000) (Fig. 4B ). For these activator lines, activity is detected at E11.5 with significantly increased activity at E14.5 and E18.5 (Perl et al., 2002) . As this is the period when VEGFR3 expression diminishes in blood endothelial cells, becoming exclusive to lymphatic endothelial cells ( Fig. 3) , activation of dnR3 was predicted to have minimal affect on the blood vasculature. As reported below and elsewhere (Mallory et al., 2006; Perl et al., 2002) , with this conditional expression system, transgene products are detected only in the lung. lungs at E13.5 with TM injection at E9.75 (A-D). LacZ+ LEC in bronchovascular region (bv) (A and B, arrows), along primary pulmonary vein (A and C, arrows) and in distal lung (A and D, arrows). Immunohistochemistry for Prox-1 in E14.5 lung (E and F) and E18.5 lung (G and H) detected LEC in primary and secondary bronchovascular regions (E and G, arrowheads) and distal lymphatics (F and H, arrows) . In (E), carets indicate Prox-1+ neuroendocrine precursor cells. In (G), note Prox-1+ cells in myofibroblast layer of primary vein (v, arrows). Scale bar = 100 lm. Whole mount analysis of Prox-1CreER T2 /R26R lungs at E18.5 with TM injection at E14.5 (I and J). In (I and J), arrows indicate primary bronchopulmonary tree and arrowheads distal lymphatics. Bv, bronchovascular region; Br, bronchioli, A, artery; V, vein.
2.3.
Inhibiting VEGFR3 activation disrupts pulmonary lymphatic development
Lungs of nontransgenic (NTG), single transgenic (dnR3 or SP-CrtTA or CCSPrtTA only), bitransgenic SP-CrtTA/(tetO) 7 -dnR3 (SP-C/dnR3) or triple transgenic SP-CrtTA/CCSPrtTA/ (tetO) 7 -dnR3 (SP-C/CCSP/dnR3) embryos were examined at E18.5 for transgene expression (Fig. 4) . Typical pulmonary lymphatics, but no dnR3 expression, was detected in the distal lung of nontransgenic (NTG) (Fig. 4C) , single transgenic embryos with Dox treatment (data not shown) or transgenic mice without Dox treatment (Fig. 4D) . In contrast, strong dnR3 expression was detected in the distal pulmonary epithelial cells of Dox-treated SP-C/dnR3 lungs (Fig. 4E) and in both Fig. 3 -VEGFR3 expression limited to lymphatics by E14.5. Immunofluorescence for VEGFR3 (green) and VEGFR2 (red) VEGFR2+/VEGFR3+(yellow) in embryonic lung from E12.5 (A), E14.5 (B) and E18.5 (C). Arrowheads denote VEGFR2+ EC and arrows denote VEGFR2/R3+ dual positive EC. Br, bronchioli; lym, lymphatic. Nuclei were stained with DAPI (blue).
* Autofluorescence of red blood cells bright yellow. Scale bar = 100 lm. Fig. 4 -Expression of dnR3 transgene reduced pulmonary lymphatics at E18.5. Constructs used to generate the lung-specific, doxycycline-regulatable dnR3 transgene expression (A and B). Dox was administered to pregnant dams beginning at E8.5 and embryonic lungs collected at E18.5 from (C) NTG, (D) SP-C/CCSP/dnR3 without Dox, (E and F) SP-C/dnR3 on Dox and (G) SP-C/ CCSP/dnR3 on Dox animals. Immunohistochemistry for VEGFR3 (C, D, E and G) and LYVE-1 (F) detected lymphatics (C-F, arrows) and dnR3 transgene expression by epithelial cells (E and G, arrowheads) . LYVE-1 also detected on pulmonary veins (F). a, artery; br, bronchioli; v, vein. Scale bar = 100 lm for (C-G), shown in (F).
distal epithelial cells and proximal and distal bronchial cells of SP-C/CCSP/dnR3 lungs (Fig. 4G) . Further the lymphatics of the bronchopulmonary bundle were hypoplastic with small atypical slit-like (collapsed and without lumens) detected with Ab to VEGFR3 (Fig. 4E and G) and Ab to LYVE-1 (Fig. 4F ) compared to control lung ( Fig. 4C and D) . Mean birth weight was not significantly different for control (1.04 g ± 0.100 SD, n = 16), SPC/dnR3 (1.01 g ± 0.120 SD, n = 12) and SP-C/CCSP/ dnR3 (1.131 g ± 0.118 SD, n = 10) mice.
The lung morphology of SP-C/CCSP/dnR3 at E18.5 was typical of the saccular stage of development (E17.5-postnatal day 5) (Ten Have-Opbroek, 1991) (Fig. 5 ). Blood vascular development and patterning, as determined by immunostaining for CD-31 (PECAM), was unaffected by dnR3 expression (Fig. 5A and B) . Further, epithelial morphology and function as determined by expression of proSP-C ( Fig. 5C and D) and aENaC ( Fig. 5E and F) were not affected by transgene expression. Dermal ( Fig. 5G and H) and mesenteric lymphatics ( Fig. 5I and J) of transgenics were indistinguishable from those of control littermates. These data demonstrate that dnR3 expression did not affect overall lung development or extrapulmonary lymphatic development.
Hypoplasia of proximal and distal lung lymphatics
The bronchovascular region of E18.5 lung has abundant lymphatic vessels embedded amongst the triad of primary bronchi/bronchioli and primary artery and vein as they enter each lobe (Fig. 6A) . Within the bronchovascular region of dnR3 lung there was variable patterning of lymphatic vessels ( Fig. 6B and C) . While the lymphatic vasculature of some dnR3 lungs was typical of E18.5 (Fig. 6B) , in other dnR3 lungs both lymphatic vessel number and total lymphatic area within the region were reduced (Fig. 6C , carets indicate region where lymphatic vessels are typically found). In contrast in distal lung ( Fig. 6D and E) the number of LEC as determined by analysis of the total number of Prox-1+ cells was uniformly reduced in dnR3 lung. Prox-1 positive cells were fourfold lower (p = 0.018) in peripheral lung of SP-C/CCSP/dnR3 (n = 6) compared to control (n = 7) (Fig. 6F ). These data demonstrate that lung-specific expression of dnR3 during organogenesis leads to lymphatic hypoplasia especially of distal conducting lymphatics and capillaries without affecting the organ morphology or blood vascular development.
2.5.
Decreased survival of dnR3 mice through postnatal day 5
Some neonatal dnR3 transgenics developed respiratory distress soon after full-term vaginal delivery and many of these died. Kaplan-Meier survival analysis of triple transgenic SP-C/CCSP/dnR3, bitransgenic SP-C/dnR3 and control mice (single and nontransgenic littermates) was performed ( Fig. 7A) (Kaplan and Meier, 1958) . There was a significant difference between the survival of SP-C/dnR3 and control neonatal mice, (p = 0.0003, log rank test) as well as SP-C/ CCSP/dnR3 and control neonatal mice (p = 0.0011, log rank test) (Fig. 7A) . There was no significant difference in the survival of SP-C/dnR3 and SP-C/CCSP/dnR3 mice. However, all neonatal deaths in the SP-C/CCSP/dnR3 mice occurred on pnd1. In contrast SP-C/dnR3 deaths were at pnd1, pnd2 and pnd5 (Fig. 7A ). These data demonstrate that lymphatic hypoplasia induced by dnR3 expression adversely affects the survival of neonatal mice. Analyses of lungs from mice dying on pnd1 showed signs of lung fluid accumulation including thickened interstitium (Fig. 7B, arrowheads) and bronchovascular cuffing, (Fig. 7B, arrows) . We hypothesized that due to poor lymphatic development, dnR3 neonatal mice were unable to efficiently clear lung fluid at birth, contributing to reduced survival.
Diminished lung fluid clearance
In mice, a rapid decline in lung wet weight versus dry weight (W/D) occurs in the first hour after birth with continued reduction over 12 h (Hummler et al., 1996) indicating lung fluid clearance. To synchronize birth and mimic delayed lung fluid clearance associated with preterm birth, pups were delivered by C-section at E18.75 and induced to breath. One hour after birth lung W/D weight ratios were significantly higher for SP-C/CCSP/dnR3 (n = 21) lungs than for control lung (n = 11) (p = 0.0066, Fig. 7C ).
Clearance of lung fluid from the airways to the interstitium is dependent on epithelial sodium channel (ENaC) function (Hummler et al., 1996) . Accumulation of lung fluid is cleared from the interstitium primarily through the venous blood vasculature. However studies in lamb estimate 11% of lung fluid is cleared through the lymphatics (Bland et al., 1982 (Bland et al., , 1980 . We predicted that pulmonary lymphatic hypoplasia would prolong fluid clearance from the interstitium. Based on the work of Bland et al. (1982 Bland et al. ( , 1980 ) and using sampling criteria approved by the American Thoracic Society (Hsia et al., 2010) , quantitative methodologies were developed to measure the area of the basement membrane around the bronchovascular bundles (bronchial cuffing) and mesenchymal thickness, specifically the periarterial interstitial compartment area. For the analyses in Fig. 7 , the lungs of control and SP-C/CCSP/dnR3 littermates were compared 1 h after C-section delivery at E18.75. Bronchial cuffing area as % total region area for SP-C/CCSP/dnR3 (n = 3) was significantly higher than for control (n = 3) littermates for both left lung (Fig. 7D ) (p = 0.021) and right lung (E) (p = 0.007). Periarterial mesenchymal area (Fig. 7F and Table 1 ) was significantly larger for SP-C/ CCSP/dnR3 (n = 3) as compared to control lung (n = 3) (p < 0.001, one-way ANOVA). These data demonstrate that diminished capacity to clear lung fluid from the interstitium may account for the poor survival in the immediate perinatal period of dnR3 mice with pulmonary lymphatic hypoplasia.
To assess the effect of lymphatic hypoplasia on type II cell maturation and surfactant synthesis, we quantified SP-B and SatPC levels 1 h after birth by C-section at E18.75 and found levels were not significantly different for control and SP-C/CCSP/dnR3 lungs ( Fig. 7G and H) . These results show that prolonged retention of lung fluid in the interstitium did not adversely affect surfactant synthesis. These data demonstrate that diminished fetal lung clearance accounts for the impaired transition to air breathing and increased mortality of SP-C/CCSP/dnR3 neonates.
Discussion
We studied the ontogeny of the pulmonary lymphatic vasculature and defined stages of pulmonary lymphatic development. The pulmonary lymphatic vasculature arises from sprouting of individual LEC from extrapulmonary lymphatics or veins (Srinivasan et al., 2007) . We show that migration of LEC along a precise path into each developing lobe as early as E11.5. Unlike the process of angiogenesis, where ''tip cells'' bud but remain attached to the stalk cell as the vessel extends, initial LEC bud then migrate into the lung parenchyma as single cells. The same process occurs as LEC first bud from the cardinal vein and migrate as solitary cells and then cluster to form initial lymph sacs (Oliver and Detmar, 2002; Oliver and Harvey, 2002) . The large lymphatics of the primary bronchovascular region form first as clusters of LEC between E12.5 and E13.5. Remodeling leads to patent lymphatic vessels in stereotypical locations within the primary bronchovascular region by E13.5 and along secondary bronchioli by E14.5. At this stage there are no significant connections between primary and secondary lymphatics. In this period single LEC within the distal mesenchyme begin to cluster to form nascent lymphatic vessels.
In the second phase of pulmonary lymphatic development, the early lymphatic vessels of the bronchopulmonary bundles and the distal LEC clusters remodel, forming a continuous lymphatic network at E18.5. This remodeling occurs through the same cellular steps as in angiogenesis with LEC tip cell budding and stalk cell expansion without individual cell migration (Xu et al., 2010) .
Others suggest that lymphatic differentiation also occurs locally from veins during organogenesis (Scalzetti et al., 1991; van der Putte, 1975a,b) . We found that cells within the myofibroblast layer associated with primary veins are Prox-1 positive. It is possible that these cells could contribute to formation of pulmonary lymphatics, especially those patterned along these veins. More precise lineage mapping techniques may determine the source of all LEC in the lung.
Pulmonary blood vascular development is required for normal alveolar development (Jakkula et al., 2000) . However, we found that pulmonary lymphatic development occurs autonomously and that neither epithelial nor blood vascular compartments were affected by lymphatic hypoplasia in the developing lung. Lung is a rich source of VEGF-D (Farnebo Fig. 6 -Pulmonary lymphatic hypoplasia with dnR3 expression. Dams were treated with Dox from E8.5, embryos isolated at E18.5. Lymphatics were identified by immunostaining for Prox-1 (arrows) in the bronchovascular regions (A-C) and distal lung (D and E) of control (dnR3only) (A and D) and SP-C/CCSP/dnR3 (B, C and E) animals. Lymphatic hypoplasia in the bronchovascular region was variable on dnR3 transgene expression ranging from indistinguishable from control (B) to significantly reduced total lymphatic area and number of Prox-1+ LEC (C). Carets in (C and E) denote stereotypic location of lymphatics. Asterisk in (D) indicates Prox-1+ cells in smooth muscle layer of large vein. Quantification (F) with the Integrated Measurement Analysis function of MetaMorph, as described in detail in Section 4, determined a fourfold reduction in the number of Prox-1+ LEC in distal lung of SP-C/CCSP/dnR3 (n = 6) compared to control (dnR3 only) (n = 7) p = 0.018. a, artery; br, bronchioli; v, vein. Scale bar = 100 lm. Greenberg et al., 2002) with small amounts of VEGF-C (Janer et al., 2006; Mallory et al., 2006) (Haiko et al., 2008) . We found similar defects in LEC migration and patterning with expression of dnR3 capable of trapping both VEGF-D Fig. 7 -Increased mortality and diminished lung fluid clearance in dnR3 transgenic mice compared to control. Kaplan-Meier survival analysis (A) of SP-C/dnR3 (n = 66) (m) and control (n = 49) (d) and SP-C/CCSP/dnR3 (n = 30) (j) and control (n = 49) (d) for animals administered Dox from E8.5 to pnd5. Analyses of thin section of lungs from a SP-C/CCSP/dnR3 pup dying of respiratory distress at pnd1 (B) showed thickened lung interstitium (between arrowheads) and perivascular cuffing (arrows). Lung fluid clearance was assessed by analysis of lung wet/dry (W/D) weight ( # p = 0.007) (C), bronchopulmonary cuffing (D left lung; * p = 0.021, and E, right lung; ** p = 0.007) and periarterial area (F) for pups delivered by C-section at E18.75 and stimulated to breath for 1 h. Critical surfactant component SatPC (G) and SP-B (H) were not significantly different for SP-C/CCSP/dnR3 (n = 5) versus control (n = 6) lungs. and VEGF-C. In dnR3 animals there were fewer LEC in distal lung and abnormal lymphatic vessels in the bronchovascular bundles. Together these data support the model that ligand binding and VEGFR3 activation are essential throughout the process of lymphatic patterning in the lung. With expression of soluble VEGFR3 driven by the keratin-14 promoter Makinen et al. (2001) found dermal lymphatics absent and only rudimentary or reduced lymphatic vessels in other organs including lung. Soluble VEGFR3 was detected in the blood circulation, yet survival was not altered by soluble K-14-VEGFR3-Ig expression. In contrast, conditional lungspecific expression of dnR3 in our model led to significant mortality in neonates. Strong activation of the SP-C and CCSP promoters during lung development resulted in robust expression of dnR3 into the lung interstitium of transgenics. We have previously used these activator lines to express transgenes in embryonic lung and found that extra-pulmonary organogenesis was unaffected (Mallory et al., 2006; Perl et al., 2002) . These results and those described here, suggest that significant levels of transgenic proteins expressed with this conditional system do not enter the blood stream. We propose that higher levels of levels of soluble dnR3 were achieved in the lungs of SP-C/CCSP/dnR3 animals than in K14-VEGFR3-Ig animals (Makinen et al., 2001 ) resulting in more robust inhibition of VEGFR3 activation and poor pulmonary lymphatic development and function.
Preterm infants born before the lymphatic and blood vasculature are fully developed are at risk for respiratory insufficiency. While lack of surfactant plays a dominant role is respiratory distress of preterm neonates, recent evidence suggests that inefficient clearance of lung fluid is also a causative factor (Helve et al., 2009) . We demonstrate that pulmonary lymphatic hypoplasia without surfactant deficit is sufficient for poor lung fluid clearance and decreased survival of neonates.
Congenital neonatal pulmonary lymphatic hypoplasia is rare but often leads to death (Thibeault et al., 2002 (Thibeault et al., , 1995 . Familial pulmonary lymphatic hypoplasia (Thibeault et al., 2002) with hypoplasia or absence of lymphatics in interlobular septa and along intra-acinar arteries is fatal for neonates. In pulmonary lymphangiectasia there is dilation of lymphatic vessels and development of lymphatic valvular incompetence (El-Chemaly et al., 2008) . Yellow nail syndrome is a rare disorder, characterized by pulmonary manifestations including bronchiectasis, pulmonary edema and pleural effusions (Hiller et al., 1972) . Data presented here suggest that diminished lung fluid clearance at birth contributes to the poor prognosis for these neonates. Therapeutic modulation of VEGFR3 could be efficacious for improving lymphatic development and diminishing respiratory distress in preterm infants and those with congenital lymphatic disorders without affecting blood vascular development and overall lung organogenesis.
4.
Experimental procedures
Tissue preparation
For embryonic tissue collection, timed-pregnant dams were euthanized by carbon dioxide inhalation and embryos removed by caesarean (C-) section as indicated from E11.5 to E18.75. Typically born at embryonic day E19.25, neonatal mice were sacrificed by decapitation. In some experiments pups were delivered by C-section at E18.75, induced to breath and sacrificed at 1 h. For this protocol, dams were exposed to carbon dioxide for 30 s and the uterus was rapidly exteriorized. With gentle pressure the pups were removed from the uterus and the placenta and amniotic sac removed. Total elapse time from initiation of carbon dioxide to cleansing of pups was less than 2 min. To stimulate breathing the pups were wiped with gauze dipped in 0.9% saline and maintained at 37°C on a heating pad. All animal procedures were conducted under the protocols approved by the Institutional Animal Care and Use Committee of Cincinnati Children's Hospital.
Histology and immunohistochemistry
Embryonic and neonatal tissues were fixed in 4% paraformaldehyde, processed and paraffin embedded under conditions optimized to maintain lung structure (Greenberg et al., 2002) . For immunohistochemistry, 4-lm sections were collected and the primary antibodies (Ab) were: Prox-1 (Fitzgerald industries, 1:300), VEGFR2 (Cell Signaling, 1:200), VEGFR3 (R&D Systems, 1:500), PECAM (BD Biosciences Pharmingen, 1:500), LYVE-1 (Novus, 1:500), aENaC (Santa Cruz, Ab200087, 1:50) and SP-C (Seven Hills Bioreagents, 1:200). Biotinylated secondary antibodies were from Vector Laboratories and fluorescent secondary antibodies conjugated to Alexa 488 and Alexa 594 were from Molecular Probes. Whole mount analysis b-galactosidase activity of Prox-1CreER T2 /Rosa and flk/LacZ lungs was detected with X-gal substrate (Sanes et al., 1986) .
Transgenic mice
The dominant-negative VEGFR3 (dnR3) construct was generated from a cDNA for the first three extracellular immunoglobulin-like (Ig) domains of the ligand binding region of murine VEGFR3 and the mouse Ig heavy chain hinge and Fc domains of mouse IgG (Hokuto et al., 2003; Tichelaar et al., 2000) . This construct was inserted between the (tetO) 7 CMV minimal promoter and a bovine growth factor polyadenylation signal to generate (tetO) 7 dnR3 construct. Blastocyst injections were performed and three independent lines with the (tetO) 7 dnR3 target construct were made. The line with highest expression of dnR3 was used in this study. Generation of the activator transgenic lines was previously described. Briefly, the rtTA gene is under the control of the 3.7 kb human surfactant protein C (SP-C) promoter that directs transgene expression to alveolar epithelial cells in peripheral lung or the 2.3 kb rat Clara cell secreted protein (CCSP) promoter that directs transgene expression to conduction airways and alveolar epithelial cells (Tichelaar et al., 2000) . Activator SP-CrtTA and/or CCSPrtTA mice were bred to (tetO) 7 dnR3 single transgenic mice to generate bitransgenic SP-CrtTA/(tetO) 7 dnR3 or CCSPrtTA/(tetO) 7 dnR3 or triple transgenic SP-CrtTA/CCSPrtTA/(tetO) 7 dn-3 (SP-C/CCSP/dnR3) mice along with nontransgenic and single transgenic (either only activator or only target construct) littermates. Genotyping was done by PCR with the following specific primers: dnR3, 5 0 -CACACAGAACTCTCCAGCATCCTG, ) and R26R were from Jackson Laboratories.
4.4.
Lung wet/dry weight, saturated phosphatidylcholine (SatPC) and surfactant protein-B (SP-B) analyses
For wet/dry analysis, after C-section delivery, with stimulation of breathing, E18.75 neonates were sacrificed and the lungs dissected with careful removal of heart and trachea. The lungs were immediately weighed using an Apex-200 balance from Denver Instruments and transferred to a 70°C oven until constant dry weight was recorded, up to 3 days. For saturated phosphatidylcholine (SatPC) analysis, lungs were homogenized in 0.2 ml of 0.9% NaCl and the protease inhibitor P8340 added (1:100, Sigma) to the homogenate. SatPC was isolated from lipid extracts (Bligh and Dyer, 1959) of the lung homogenates using osmium tetroxide method (Mason et al., 1976) followed by phosphorous content assay (Hess and Derr, 1975) . SP-B was determined by quantitative western analysis with Ab 3426 (Chemicon) recognizing mature SP-B. Significance was determined by Student's t test.
Morphometric analyses
MetaMorph software, version 6.1, and modifications of the protocols described by Bland et al. (1982 Bland et al. ( , 1980 and sampling criteria of Hsia et al. (2010) were used to quantify (a) the number of Prox-1+ LEC per unit area of lung, (b) cuffing around the primary bronchovascular bundle and (c) relative periarterial area. To mask sample treatment, tissue blocks from each animal were assigned a unique code that was unknown to the investigator. (a) Quantification of Prox+ LEC in distal lung. Transverse thin sections of lung tissue (4 lM) were selected using a random start point (Hsia et al., 2010) with subsequent sections (3-5), each 12 lm apart. Sections were immunostained with the Ab to Prox-1 and 10· photomicrographs taken. The Integrated Measurement Analysis function of MetaMorph was used to determine lung area excluding the primary bronchovascular region. The total number of Prox-1+ cells was determined. Prox-1+ epithelial cells of developing neuroendocrine lineage and smooth muscle cells of veins were excluded. Data are reported as number of Prox-1+ cells per unit lung area, with significance determined by ANOVA for n = 6-7 lungs in each treatment group. (b) Analysis of cuffing in bronchovascular bundle. Transverse sections of the bronchovascular region were selected based on 'landmarks' in the region of the connection between trachea and lung including the triad of primary bronchi/bronchioli, arteries and veins. Alternate sections were stained with panAb for cytokeratin to identify epithelium and with Ab to Prox-1 to identify lymphatics (Wigle and Oliver, 1999 ) and 3-5 sections for each lung used for quantification. Using 10· photomicrographs of cytokeratin-stained sections to delineated epithelial boundaries, the Integrated Measurement Analysis function of MetaMorph was utilized to determine the area of the primary bronchovascular region or 'region area, Ar'. Areas of bronchi (Ab), arteries (Aa), veins (Av) and lymphatics (Al) were determined similarly, with lymphatic identification confirmed by comparison of serial sections stained with Ab to Prox-1. Bronchi, blood vessel and lymphatic areas were subtracted from the region area to quantify 'effective cuffing area' [Ar À (Ab + Aa + Av + Al) = cuff area] and reported as relative cuff area [cuff/Ar · 100]. Mean, standard error of the mean and the significance were determined using Student's t test for n = 3 littermates in each group. (c) Relative periarterial interstitial area. Transverse thin sections (5) of lung tissue (4 lM) were selected using a random start point for each sample. Size of the periarterial interstitial compartment in the mesenchyme was determined by measurement of the area around arteries with lumens of less than 20 lm in 7-18 independent fields of each section. Boundaries of the periarterial interstitial mesenchymal compartment were delineated by cytokeratin stain of the epithelium and the total area determined as area of mesenchyme (Am). The area of the artery (Aa) including endothelium and lumen was determined. Results are reported as area mesenchyme/ total arterial area. Mean, standard error of the mean and the significance were determined using ANOVA for a minimum of n = 6 in each group.
